Starpharma Holdings Ltd
ASX:SPL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shenzhen Xinyichang Technology Co Ltd
SSE:688383
|
CN |
|
A
|
Alfa Holdings SA
BOVESPA:RPAD3
|
BR |
|
Wabash National Corp
NYSE:WNC
|
US |
|
R
|
ROPEOK Technology Group Co Ltd
SSE:688619
|
CN |
|
Marzetti Co
NASDAQ:MZTI
|
US |
|
G
|
Ganzhou Tengyuan Cobalt New Material Co Ltd
SZSE:301219
|
CN |
|
IRLAB Therapeutics AB
STO:IRLAB A
|
SE |
|
AVT Natural Products Ltd
NSE:AVTNPL
|
IN |
|
Goodfood Market Corp
TSX:FOOD
|
CA |
|
T
|
TATA Health International Holdings Ltd
HKEX:1255
|
HK |
|
Gree Electric Appliances Inc of Zhuhai
SZSE:000651
|
CN |
|
Mayfield Group Holdings Ltd
ASX:MYG
|
AU |
|
EnPro Industries Inc
NYSE:NPO
|
US |
|
S
|
Space Hellas SA
XBER:H9LA
|
GR |
|
L
|
Localiza Rent a Car SA
BOVESPA:RENT3
|
BR |
|
Inner Mongolia Dian Tou Energy Corp Ltd
SZSE:002128
|
CN |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (10.7), the stock would be worth AU$-0.11 (116% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -67.6 | AU$0.68 |
0%
|
| Industry Average | 10.7 | AU$-0.11 |
-116%
|
| Country Average | 16.8 | AU$-0.17 |
-125%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Starpharma Holdings Ltd
ASX:SPL
|
285.5m AUD | -67.6 | -88.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
869.1B USD | 30.4 | 42.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.5B USD | 21.7 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.2 | 19.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.9B GBP | 23.4 | 30 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
289.8B USD | 12 | 15.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228B CHF | 16.1 | 20.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 9.6 | 11.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.5B USD | 10.3 | 20.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119B USD | 8.8 | 16.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10.7 |
| Median | 16.8 |
| 70th Percentile | 24.5 |
| Max | 6 797.5 |
Other Multiples
Starpharma Holdings Ltd
Glance View
Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. The company is headquartered in Melbourne, Victoria and currently employs 50 full-time employees. The company went IPO on 2000-09-28. The firm is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The firm has two core development programs: VivaGel portfolio and Dendrimer Enhanced Product (DEP) drug delivery. VivaGel BV for bacterial vaginosis (BV) is a women’s health product. The company is available for sale under the brand names, Betafem BV Gel (UK), Betadine BV (Europe), Betadine BV Gel (Asia) and Fleurstat BVgel (Australia and New Zealand). DEP is a drug delivery platform, which provides demonstrated reproducible preclinical benefits across various internal and partnered DEP programs, including improved efficacy, safety, and survival. The firm has three internal DEP products includes DEP docetaxel, DEP cabazitaxel and DEP irinotecan. These internal DEP Products are in clinical development. The firm develops several products internally and others via commercial partnerships.
